Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants.

Authors:
Address: Department of Pediatrics, Phramongkutklao Hospital, Bangkok, Thailand. veerachaiw@yahoo.com
Journal:

Publication:

abstract

A Phase I/II observer-blind, randomized, controlled trial evaluated the Safety and immunogenicity of a dengue virus (DENV) vaccine candidate in healthy Thai infants (aged 12-15 months) without measurable pre-vaccination neutralizing antibodies to DENV and Japanese encephalitis virus. Fifty-one subjects received two doses of either DENV (N = 34; four received 1/10th dose) or control vaccine (N = 17; dose 1, live varicella; dose 2, Haemophilus influenzae type b). After each vaccine dose, adverse events (AEs) were solicited for 21 days, and non-serious AEs were solicited for 30 days; serious AEs (SAEs) were recorded throughout the study. Laboratory safety assessments were performed at 10 and 30 days; neutralizing antibodies were measured at 30 days. The DENV vaccine was well-tolerated without any related SAEs. After the second dose, 85.7% of full-dose DENV vaccinees developed at least trivalent and 53.6% developed tetravalent neutralizing antibodies ≥ 1:10 to DENV (control group = 0%). This vaccine candidate, therefore, warrants continued development in this age group (NCT00322049; clinicaltrials.gov).

Related Articles
A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.
PLoS Negl Trop Dis. 2011
A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.
Durbin AP, Whitehead SS, Shaffer D, Elwood D, Wanionek K, Thumar B, Blaney JE, Murphy BR, Schmidt AC. PLoS Negl Trop Dis. 2011 Aug; 5(8):e1267. Epub 2011 Aug 2.
Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.
Am J Trop Med Hyg. 2008
Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.
Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak JR, Eckels KH, Hutagalung Y, et al. Am J Trop Med Hyg. 2008 Mar; 78(3):426-33.
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
Hum Vaccin. 2009
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, et al. Hum Vaccin. 2009 Jan-Feb; 5(1):33-40. Epub 2009 Jan 27.
Review From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Vaccine. 2011
Review From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. Vaccine. 2011 Sep 23; 29(42):7229-41. Epub 2011 Jul 13.
Review Dengue vaccine candidates in development.
Curr Top Microbiol Immunol. 2010
Review Dengue vaccine candidates in development.
Durbin AP, Whitehead SS. Curr Top Microbiol Immunol. 2010; 338:129-43.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.